We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Likely Flaws Uncovered for LM-Method for Lyme Disease Detection

By LabMedica International staff writers
Posted on 12 Jul 2016
According to a new study, the recently developed modified microscopy technique “LM-method” of examining blood samples to help diagnose Lyme disease (and babesiosis) – is unable to distinguish infected patients from healthy controls, yielding many false-positive results.

While most people who contract Lyme disease recover quickly after antibiotic treatment, up to 20% of patients report persistent symptoms years after being told standard tests are negative for the disease. More...
Interest in new diagnostic tests is therefore high.

The tick vector Ixodidae transmits Borrelia (bacterial causative agent of Lyme disease) as well as Babesia (parasitic protozoan causative agent of babesiosis). The new research follows up on a previous study suggesting that LM-method could detect active cases of disease caused by Borrelia and/or Babesia in just 1-2 days. Considerable publicity, and thereby patient demand, for this test in Norway continued despite that earlier studies did not include a control group and methods were not validated and ready for use in patients.

To investigate the reliability of the new test, Dr Audun Aase, from the Norwegian Institute of Public Health (Oslo, Norway), and colleagues collected blood samples from people who had been suffering from Lyme disease-like symptoms for several years and previously tested positive for Borrelia and/or Babesia infection using LM-method (21 people), and from healthy controls with no known history of tick bites (41 people). The samples were then masked and analyzed in independent laboratories using a range of diagnostic tests including the LM-method, conventional microscopy, genetic fingerprint testing (PCR), and serology.

The study indicated that LM-method results in high numbers of false positives: 14 (66%) patient-group samples and 35 (85%) control-group samples were judged positive for Borrelia and/or Babesia. However, only 1 sample (5%) of the patient-group and 8 samples (20%) of the control-group tested positive for Borrelia DNA by PCR. None of the samples were positive for Babesia DNA, and conventional microscopy did not identify Babesia in any of the samples. In conclusion, the structures interpreted as Borrelia and Babesia using LM-method could not be verified by PCR and the LM-method was thus falsified.

In an accompanying editorial commentary, Dr Ram B. Dessau, infectious diseases expert and senior consultant at Slagelse Hospital (Slagelse, Denmark), wrote: “I hope the study serves as a warning against non-validated microscopic procedures and helps prevent mismanagement of patients with chronic complaints, who are lured to seek improper diagnosis in the future.”

The study, by Aase A et al, was published online February 2016 in the journal Infectious Diseases.

Related Links:
Norwegian Institute of Public Health



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.